Literature DB >> 1503399

Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen.

S F Stinson1, M C Alley, W C Kopp, H H Fiebig, L A Mullendore, A F Pittman, S Kenney, J Keller, M R Boyd.   

Abstract

A panel of 60 human tumor cell lines is currently being used in the U.S. National Cancer Institute's in vitro anticancer drug screen. The panel is organized into 7 subpanels; 6 leukemia/lymphoma lines comprise one subpanel, and 54 other lines are organized into subpanels representing solid tumors of the central nervous system (CNS), colon, lung, ovaries, kidneys and melanomas. In the present study, the leukemia and lymphoma cell lines were analyzed by flow cytometry for appropriate CD antigens; all but 1 line showed patterns of expression consistent with their reported derivations. The solid tumor lines were characterized individually using morphological and immunocytochemical techniques to determine their relative degrees of representativity for the subpanels within which they are currently grouped. Histological, histochemical and ultrastructural examinations were performed on cell lines grown under identical conventional culture conditions and as xenografts in nude mice. Immunocytochemistry using panels of antibodies raised against 6 types of intermediate filaments, 7 adenocarcinoma-associated antigens, 7 melanoma/neuro-ectodermal-associated antigens, 3 neuroendocrine-associated antigens, 9 urinary tract associated antigens, and 4 markers of muscle differentiation was done on cells grown in monolayer culture. Central nervous system (CNS) cell lines lacked expression of glial fibrillary acidic protein, but all had other features consistent with derivation from glioblastoma. Lines derived from adenocarcinomas of the colon, lung and ovary, for the most part, expressed adenocarcinoma-associated antigens and showed histological and/or ultrastructural evidence of gland formation and other adenomatous features. Most of these lines were poorly differentiated. Lines derived from large-cell and squamous-cell cancers also showed some characteristics consistent with their reported origins, except for one line which showed immunocytochemical and morphologic characteristics consistent with rhabdomyosarcoma. The 2 lines derived from small cell lung cancer (SCLC) lacked neurosecretory granules and 3 other SCLC markers but showed morphologic features consistent with SCLC. Most melanoma cell lines strongly expressed melanoma-associated antigens and were morphologically similar to human melanoma. Five lines produced premelanosomes, melanosomes or melanin. Most of the renal cancer cell lines showed morphologic or immunocytochemical features consistent with renal clear cell carcinoma. Collectively, these morphological and immunocytochemical analyses provide information concerning tissue of origin, tumor type, degree of differentiation and other biologic features essential to the use of these lines in a disease-oriented in vitro antitumor drug screen and to the interpretation of data derived therefrom.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1503399

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  44 in total

Review 1.  The complexity of radiation stress responses: analysis by informatics and functional genomics approaches.

Authors:  A J Fornace; S A Amundson; M Bittner; T G Myers; P Meltzer; J N Weinsten; J Trent
Journal:  Gene Expr       Date:  1999

2.  Chemosensitivity prediction by transcriptional profiling.

Authors:  J E Staunton; D K Slonim; H A Coller; P Tamayo; M J Angelo; J Park; U Scherf; J K Lee; W O Reinhold; J N Weinstein; J P Mesirov; E S Lander; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

3.  mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities.

Authors:  Hongfang Liu; Petula D'Andrade; Stephanie Fulmer-Smentek; Philip Lorenzi; Kurt W Kohn; John N Weinstein; Yves Pommier; William C Reinhold
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

4.  Analysis of protein expression in cell microarrays: a tool for antibody-based proteomics.

Authors:  Ann-Catrin Andersson; Sara Strömberg; Helena Bäckvall; Caroline Kampf; Mathias Uhlen; Kenneth Wester; Fredrik Pontén
Journal:  J Histochem Cytochem       Date:  2006-09-06       Impact factor: 2.479

5.  The role of gene expression profiling in early-stage non-small cell lung cancer.

Authors:  Wenlong Shao; Daoyuan Wang; Jianxing He
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

6.  Primary anti-proliferative activity evaluation of 1-(quinolizidin-1'-yl)methyl- and 1-(ω-tert-amino)alkyl-substituted 2-phenyl-, 2-benzyl- and 2-[(benzotriazol-1/2-yl)methyl]benzimidazoles on human cancer cell lines.

Authors:  Michele Tonelli; Bruno Tasso; Lorenzo Mina; Giuseppe Paglietti; Vito Boido; Fabio Sparatore
Journal:  Mol Divers       Date:  2013-04-13       Impact factor: 2.943

7.  Multifactorial regulation of E-cadherin expression: an integrative study.

Authors:  William C Reinhold; Mark A Reimers; Philip Lorenzi; Jennifer Ho; Uma T Shankavaram; Micah S Ziegler; Kimberly J Bussey; Satoshi Nishizuka; Ogechi Ikediobi; Yves G Pommier; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

8.  CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.

Authors:  Augustin Luna; Fathi Elloumi; Sudhir Varma; Yanghsin Wang; Vinodh N Rajapakse; Mirit I Aladjem; Jacques Robert; Chris Sander; Yves Pommier; William C Reinhold
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

9.  Two CD95 tumor classes with different sensitivities to antitumor drugs.

Authors:  Alicia Algeciras-Schimnich; Eric M Pietras; Bryan C Barnhart; Patrick Legembre; Shrijay Vijayan; Susan L Holbeck; Marcus E Peter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

Review 10.  Clinical impact of high-throughput gene expression studies in lung cancer.

Authors:  Jennifer Beane; Avrum Spira; Marc E Lenburg
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.